SubsidieMeestersNext generation HPC/QC in silico drug discovery platform for de novo design
ATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027.
Projectdetails
Introduction
ATLAS is a powerful in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing. The platform is the result of decades of research by leading experts in molecular dynamics. The technology is grounded on over 100 peer-reviewed papers and two ERC grants.
Achievements
Our beta code has gathered important accolades, including:
- The prestigious ATOS-Joseph Fourier prize
- First place at the foremost rational drug design competition, the SAMPL challenge
Benefits of ATLAS
ATLAS can replace costly and laborious experiments. It can even run entire drug discovery campaigns in silico, reducing cycle times and costs by at least 50%.
Future Goals
By 2027, we will have a 35-project portfolio, and the first ATLAS-generated compound will reach the clinic. Thereafter, our objective is to generate a new candidate every 18 months.
Team Expansion and Market Strategy
That year, our team will surpass 50 people, and we will expand into the US market. We aim at securing a leadership position in the nascent in-silico drug discovery market.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.249.375 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-8-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- QUBIT PHARMACEUTICALSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The first utility-oriented, agnostic software platform for quantum-centric drug discoveryKvantify is developing Kvaser, a user-friendly quantum software tool for R&D scientists to perform advanced molecular simulations, enhancing drug discovery with speed and precision. | EIC Accelerator | € 2.499.999 | 2023 | Details |
BioSim M2M: Molecules to MedicineBioSimulytics' BioSim M2M technology accelerates pharmaceutical R&D by predicting stable crystal structures and binding poses, reducing analysis time from 3 months to 3 weeks. | EIC Accelerator | € 2.499.525 | 2023 | Details |
Multi-omic data driven drug discovery and indication prioritisation platform in oncologymCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies. | EIC Accelerator | € 2.495.788 | 2022 | Details |
Human-Centric AI platform for heALth and Life sciencesAbzu ApS aims to revolutionize AI in pharma with the QLattice, a user-friendly, explainable platform that enhances R&D efficiency and reduces costs, supported by EIC funding. | EIC Accelerator | € 2.495.099 | 2023 | Details |
Closed-loop deep learning in early-stage drug discovery - cloud platform for targeted protein degradationCeleris Therapeutics leverages deep learning to develop a web platform for degrading undruggable proteins, aiming to revolutionize drug discovery for incurable diseases like Alzheimer's and cancer. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The first utility-oriented, agnostic software platform for quantum-centric drug discovery
Kvantify is developing Kvaser, a user-friendly quantum software tool for R&D scientists to perform advanced molecular simulations, enhancing drug discovery with speed and precision.
BioSim M2M: Molecules to Medicine
BioSimulytics' BioSim M2M technology accelerates pharmaceutical R&D by predicting stable crystal structures and binding poses, reducing analysis time from 3 months to 3 weeks.
Multi-omic data driven drug discovery and indication prioritisation platform in oncology
mCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies.
Human-Centric AI platform for heALth and Life sciences
Abzu ApS aims to revolutionize AI in pharma with the QLattice, a user-friendly, explainable platform that enhances R&D efficiency and reduces costs, supported by EIC funding.
Closed-loop deep learning in early-stage drug discovery - cloud platform for targeted protein degradation
Celeris Therapeutics leverages deep learning to develop a web platform for degrading undruggable proteins, aiming to revolutionize drug discovery for incurable diseases like Alzheimer's and cancer.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Automated, miniaturized and accelerated drug discovery: AMADEUSAMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility. | ERC Advanced... | € 3.409.401 | 2024 | Details |
Drug Discovery IntelligenceHet project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties. | Mkb-innovati... | € 20.000 | 2020 | Details |
Artificial Scientific Discovery of advanced Quantum Hardware with high-performance SimulatorsARTDISQ aims to leverage AI and high-performance simulators to automate the design of advanced quantum experiments, enhancing discoveries in gravitational wave detection and imaging systems. | ERC Starting... | € 1.499.221 | 2025 | Details |
Turning gold standard quantum chemistry into a routine simulation tool: predictive properties for large molecular systemsThis project aims to develop advanced quantum simulation methods for large molecules, enhancing predictive power and efficiency to study complex biochemical interactions and reactions. | ERC Starting... | € 1.175.215 | 2023 | Details |
Cloudplatform for High Content ImagingCore Life Analytics ontwikkelt een cloudplatform voor onafhankelijke onderzoekers om snel en kosteneffectief HC data-analyse uit te voeren. | Mkb-innovati... | € 20.000 | 2023 | Details |
Automated, miniaturized and accelerated drug discovery: AMADEUS
AMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility.
Drug Discovery Intelligence
Het project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties.
Artificial Scientific Discovery of advanced Quantum Hardware with high-performance Simulators
ARTDISQ aims to leverage AI and high-performance simulators to automate the design of advanced quantum experiments, enhancing discoveries in gravitational wave detection and imaging systems.
Turning gold standard quantum chemistry into a routine simulation tool: predictive properties for large molecular systems
This project aims to develop advanced quantum simulation methods for large molecules, enhancing predictive power and efficiency to study complex biochemical interactions and reactions.
Cloudplatform for High Content Imaging
Core Life Analytics ontwikkelt een cloudplatform voor onafhankelijke onderzoekers om snel en kosteneffectief HC data-analyse uit te voeren.